Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Follow-Up Trial to Evaluate Long-Term Safety and Antibody Persistence, and the Impact of a Booster Dose of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescents and Adults in Areas Non-Endemic for Dengue

NCT03999996 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT03999996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03999996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Follow-Up Trial to Evaluate Long-Term Safety and Antibody Persistence, and the Impact of a Booster Dose of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescents and Adults in Areas Non-Endemic for Dengue
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
November 12, 2019
Completion date
May 25, 2024
Enrollment
365 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

dengue fever